Survodutide dosage: reported doses and schedule

Typical reported dose: 0.3 mg once a week

• Phase 2 diabetes: 0.3 mg: 0.3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 0.9 mg: 0.3 mg once weekly, then 0.6 mg once weekly, then 0.9 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.8 mg: 0.3 mg once weekly, then 0.6 mg once weekly, then 0.9 mg once weekly, then 1.2 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 2.7 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 1.8 mg once weekly, then 2.4 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.2 mg twice weekly: 0.3 mg twice weekly, then 0.6 mg twice weekly, then 0.9 mg twice weekly, then 1.2 mg twice weekly twice weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.8 mg twice weekly: 0.3 mg twice weekly, then 0.6 mg twice weekly, then 0.9 mg twice weekly, then 1.2 mg twice weekly twice weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)

Highest studied: Highest published weekly SC target found: 6 mg..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator